- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00292318
Treatment of Patients With Fecal Incontinence
August 13, 2015 updated by: US Department of Veterans Affairs
Biofeedback Therapy for Fecal Incontinence a Randomized Control Trial
The purpose of this study is to determine if a behavioral treatment method called biofeedback will reduce the frequency of episodes of leakage of fecal material in patient suffering from fecal incontinence.
Study Overview
Status
Terminated
Conditions
Detailed Description
Fecal incontinence (FI) is a devastating condition that causes psychological stress, shame, embarrassment, and social isolation.
It has a major impact on quality of life of patients and their families.
It complicates medical illnesses and management, has major economic consequences and can contribute to early nursing home placement.
Although FI affects 2.2% to 11% of the general population, the magnitude of the problem is underestimated, since most patients do not discuss this silent affliction with their care providers.
In uncontrolled studies of biofeedback for FI, including our preliminary observations in male veterans without anal sphincter injury, improvement was observed in up to 80% of patients.
However, it may not be appropriate for all patients.
One recent randomized, controlled trial in predominantly (93% women) female patients, many (> 60%) with post-obstetrical anal sphincter injury, reports that biofeedback is no more effective than medical therapy alone.
The trial provides data for the formulation of an evidence-based approach to treat FI in female veterans.
There are no randomized, controlled data on the effectiveness of biofeedback for FI in male patients.
A randomized, controlled trial is needed to assess the effectiveness of multi-component biofeedback therapy versus standard medical therapy in man.
The immediate objectives of the current proposal are to evaluate the effectiveness of biofeedback treatment for FI and to identify baseline patient characteristics that will predict improvement and adequate relief in FI symptoms following treatment.
This will lead directly to our long-term goal of providing optimal treatment for FI by tailoring biofeedback plus medical therapy to each patient's needs, based on sound clinical evidence.
This project is a prospective, randomized, controlled clinical trial comparing two treatments for FI among patients who have failed medical treatment under the care of their primary care providers and are referred for evaluation and management of current FI.
As part of standard care, all referred patients will receive a history and physical examination, including medical, surgical, FI-specific symptoms and physical findings (general, mobility, mental status and anorectal examination).
Those who meet inclusion criteria and who agree to participate will be randomly assigned to one of 2 study arms: 1. medical therapy alone, 2. medical therapy + sphincter strength + sensation + coordination training.
Baseline data will also include adequate relief measure, incontinence scores based on bowel habit diary, anorectal parameters based on manometric and sensory testing, general and FI-specific quality of life, depression, anxiety, and expectation of improvement following treatment.
All questionnaires will be based on published, validated instruments.
Patients will be treated in six biweekly sessions (3 months).
Medical therapy (six 40 - 60 minute sessions) includes advice, medication for constipation/diarrhea, and instruction related to empiric anal sphincter exercises (group 1).
Biofeedback treatment (six 40 - 60 minute sessions) includes medical therapy plus all components of biofeedback (groups 2).
Follow up data will be obtained in all patients at the end of treatment (3 months) and by mailed questionnaires at 12 months after completion of treatment or dropout.
We can determine if biofeedback plus medical therapy will be superior to medical therapy alone in providing FI symptom relief.
The possibility that more patients will report relief of FI symptoms when specific deficit(s) detected at baseline testing show(s) improvement with treatment.
The influence of co-variables on results of treatment can also be determined.
Our long term goal is to develop a clinically relevant strategy that will be cost-effect for the management of FI in VA patients (predominantly male) within the organizational frame work of primary and subspecialty care.
If biofeedback treatment is proven to be effective, and VA patients can be offered therapy components with optimal likelihood of success, the obvious benefit to our VA patients is abatement of the silent affliction of FI and improvement in patient satisfaction and quality of life.
Further study will focus on a multi-site cooperative study to assess which component of biofeedback is most instrumental in bringing about improvement and relief in patients with specific deficits.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sepulveda, California, United States, 91343
- VA Greater Los Angeles Healthcare System, Sepulveda, CA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male or female patient with inadequate relief of fecal incontinence symptoms after documented management in the primary care setting. They must have:
- a mini-mental status score of > 18
- an "up and go" test score of < 30 seconds
- bowel habit diary showing > one episode of fecal incontinence episode per week
Exclusion Criteria:
- patients who previously underwent a course of biofeedback for fecal incontinence
- age < 18 years
- major neurological disease
- significant cognitive impairment (mini mental status examination score < 18), functional impairment (up and go score of > 30 seconds)
- active inflammatory bowel disease
- history of spinal cord injury
- rectal resection
- ileal pouch procedures
- latex allergy
- significantly distressed and unable to consider informed consent issues adequately
- needing urgent medical referral
- insufficient written English skills to complete the questionnaires
- require surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1
Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
|
Medical counseling and ano-sphinctal exercises.
|
Experimental: Arm 2
Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
|
Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Report of "Adequate Relief" From FI Symptoms With a "Yes" Answer Will be Used as Primary Outcome Variable. Data Will be Recorded at End of Treatment. A "Responder" Will be Defined as One Who Provides a "Yes" Answer.
Time Frame: The primary outcome will be determined at the end of the study which will be 20 weeks after starting the study.
|
Only reporting the results of participants who reported adequate relief.
|
The primary outcome will be determined at the end of the study which will be 20 weeks after starting the study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Anorectal Physiologic Tests (Absolute Squeeze Pressure)
Time Frame: The secondary outcome will be determined at the end of the study which will be 20 weeks after starting the study.
|
Measurement of pressure changes by a colonoscope as recorded by a manometric catheter connected to a Polygraph transducer.
|
The secondary outcome will be determined at the end of the study which will be 20 weeks after starting the study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Felix W Leung, MD, VA Greater Los Angeles Healthcare System, Sepulveda, CA
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
February 13, 2006
First Submitted That Met QC Criteria
February 13, 2006
First Posted (Estimate)
February 15, 2006
Study Record Updates
Last Update Posted (Estimate)
August 19, 2015
Last Update Submitted That Met QC Criteria
August 13, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-013-05S
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
Batterjee Medical CollegeBenha UniversityCompleted
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
Hospital Mutua de TerrassaCompletedGas Incontinence | Soilings, Fecal
-
RDD Pharma LtdWithdrawnIdiopathic Fecal IncontinenceIsrael
-
Nantes University HospitalCompletedConstipation Aggravated | Fecal Incontinence With Fecal UrgencyFrance
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
University of AarhusUniversity of Tromso; Hvidovre University HospitalCompletedFecal Incontinence | Faecal IncontinenceDenmark
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Massarat ZutshiCook Group IncorporatedTerminatedFecal Incontinence | Anal IncontinenceUnited States
Clinical Trials on control group
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Henan Cancer HospitalRecruitingChemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric CarcinomaChina
-
International University of La RiojaRecruiting
-
The University of Hong Konghong Kong Cancer FundCompletedBreast Cancer | Yoga Therapy | Shoulder Joint Motion | Scar Contracture
-
Romanian Society of Anesthesia and Intensive CareUniversity of Medicine and Pharmacy "Victor Babes" Timisoara; Timişoara County...Completed
-
University of PernambucoUnknown
-
Yonsei UniversityUnknownAdvanced Gastric Cancer | Neoadjuvant Chemotherapy | Palliative ChemotherapyKorea, Republic of
-
Physicians Committee for Responsible MedicineMetropolitan Police Department of Washington, D.C.SuspendedDiabetes Mellitus, Type 2 | Overweight | Blood PressureUnited States
-
Beijing Tiantan HospitalNot yet recruitingIschemic Stroke | Post-stroke Cognitive Impairment